T cell therapy player Lyell prepares to open $65M manufacturing facility in the Seattle area
When Stephen Hill was living in Puerto Rico and Maryland, overseeing the drug manufacturing arms for Amgen and AstraZeneca, each photo his family posted on Facebook made him miss his home state of Washington a little bit more. His dad standing in a river, holding a freshly caught steelhead trout. Others making fresh apple cider at his grandfather’s farm.
But today, Hill’s back home, overseeing the opening of Lyell Immunopharma’s new $65 million manufacturing center as the firm’s chief technical operations officer.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 107,500+ biopharma pros reading Endpoints daily — and it's free.